Digital Innovation in the Treatment of Cancer

Back to results

Winner

MDT-FIT (Multidisciplinary Team Feedback for Improving Teamworking); A toolkit to improve patient care across the whole cancer pathway

By Barts Health NHS Trust, Kings College London and Green Cross Medical Ltd

MDT-FIT is a web-based platform that enables individual MDTs, Trusts and networks/systems to complete and oversee a three-stage process, incorporating self-assessment against The Characteristics of an effective MDT, independent observation, anonymised feedback and facilitated team discussion. The aim is to improve the quality of service and benefit patient care. It facilitates team working and quality improvement at low cost and takes little time. It is also repeatable, allows issues to be prioritised and supports “benchmarking” across teams and services.

What is MDT Fit? 

A user’s guide

Judges’ comments

“This work is all about improving teamwork and will ultimately benefit every single patient that is discussed by the MDT and it should be incorporated into standard practice across the NHS. Its evaluation was almost carried out to clinical trial levels and it deserves to be more widely known – this is the kind of thing that should have been in the Cancer Plan.”

 

Commended

ONCOassist – CE approved clinical decision support app

By ONCOassist/Portable Medical Technology Ltd

ONCOassist is a revolutionary new CE approved smartphone app developed specifically for oncology professionals. ONCOassist currently averages over 2,500 active users per month. The application contains all the decision support tools oncology professionals need at point-of-care, freeing them from the need to conduct time-consuming online searches. Tools include useful formulas, prognostic algorithms, adjuvant decision support tools similar to adjuvant online, AJCC staging content, CTCAE v4.0.

Judges’ comments

“This was a big commercial project with much clinical testimony to support it. The work produced an innovative digital tool and the judges praised it for achieving a CE marking to show that it complies with EU safety, health and environmental requirements.”

QiC Oncology 2016 partner:
Bristol-Myers Squibb
Supported by: